Towards novel translational safety biomarkers for adverse drug toxicity

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2007
  • Initiating Organization: TI Pharma
  • Initiator Type: Nonprofit foundation
  • No disease focus
  • Location: International

Abstract

Mission

This project studies the metabolic effects of eight drugs (among which are paracetamol and diclofenac) with known side effects in the liver. By looking into the mechanics on a level ranging from the molecule to the patient, the researchers in this project aim to find biomarkers and develop tools for the early prediction of side effects of drugs. One of the breakthroughs in the project is the discovery that a person’s genetic profile appears to be one of the mechanics that have an influence on the resistance to adverse drug reactions. The ability to identify adverse effects in an early stage will prevent much discomfort in patients and economic loss.

Impact/Accomplishment

This project resulted in five Ph.D. theses:

Sponsors & Partners

Abbott

BioDetection Systems BV

 BioFocus DPI

Leiden University

MSD

NOTOX BV

PamGene

Pepscan Presto BV

Radboud University Nijmegen Medical Centre

University of Gronigen

Utrecht University

VU University Amsterdam


Last Updated: 04/07/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.